Targeted and immune therapies now spare eyes and orbits in periocular cancer, making multidisciplinary care the standard.
Mainly for locally advanced disease. The clearest indication is a patient who would otherwise need orbital exenteration, or AJCC T4 disease, greater than 30 millimeters and invading the orbit. Surgery cures most cases with good reconstruction, so drugs are not used for cancers that are surgically treatable. Stage three eyelid melanoma with nodal spread is another indication.
Answered around 16:39Take enough tissue rather than a superficial sliver, avoid crushing the specimen, and do not biopsy with cautery; excise with scissors or a blade. If melanoma is suspected, excise a larger, deeper area rather than shaving, because tumor thickness may decide whether a sentinel lymph node biopsy is needed. Talk to your pathologist in advance if unsure.
Answered around 9:18Avoid the ulcerated center of a basal cell carcinoma, where the pathologist may see only necrotic tissue. Biopsy the margin where normal and neoplastic tissue meet for a higher yield. Target the tissue for your differential: for basal cell include all epidermis and dermis; for sebaceous carcinoma go to the tarsus, where it originates.
Answered around 13:19The median time to response is about 1.9 months, so after two doses there is usually a clear picture. Patients are reassessed after the second dose so a surgical window is not missed. A paper in press found almost all benefit came within the first two doses, suggesting treatment duration will be reduced over the next few years.
Answered around 25:41At Michigan, patients are treated for one year and then followed. Pain from trigeminal involvement mostly resolves, and around four to six months later facial and extraocular nerve function starts to recover. Survival was around 85% at two years and about 75% at three years, whereas patients treated with radiation before immunotherapy often did not survive a year.
Answered around 30:49Many patients develop some form of inflammation, most commonly diarrhea and dermatitis, plus thyroid, adrenal and other autoimmune problems. Ocular complications such as visual loss or uveitis occur in about 1% or less, and fatal side effects in about 1%. Overall rates are about 25-30% for a single agent like PD-1, rising to 50% or more with combination therapy.
Answered around 33:41Surgically manageable tumors get wide excision combined with sentinel lymph node biopsy, an approach supported by NCCN guidelines. This replaced empiric radiation of regional lymph nodes. Depending on results, patients are followed or given adjuvant immunotherapy or external beam radiotherapy. Immunotherapy is increasingly used and Merkel cell survival has doubled over the last decade.
Answered around 37:00Across the board, giving immunotherapy in the neoadjuvant setting shows about a 20% improvement in outcomes compared with giving it as definitive therapy. So with regional nodal disease, neoadjuvant therapy is increasingly considered up front, and surgeons in cutaneous disease are doing less surgery, relying on adjuvant immunotherapy or targeted therapy afterward.
Answered around 20:47Both are unfamiliar to most medical oncologists. In both, about 50% of metastases occur during follow-up. Sebaceous carcinoma has a nodal predilection, so blanket CT and brain MRI workups do little. Conjunctival melanoma, like skin melanoma, carries a brain metastasis risk and is not mucosal melanoma. Panelists order their own systemic workups, at least yearly.
Answered around 56:31One panelist calls it her least favorite practice. When canaliculi are gone, focus on lower eyelid position and attach it at the posterior lacrimal crest. Placing a Jones tube, sometimes even after radiation, in patients who lost medial canthal tissue and canaliculi causes horrible dry eyes because it drains away the remaining tears.
Answered around 54:01“As pathologists, we really don't care if you're right or wrong, but the information that's on the sheet is really helpful.”
“So please send it to the pathology.”
“So, we definitely know that overall, the survival for Merkel cell patients has doubled over the last decade, largely due to the introduction of immunotherapy.”
“So I'm a cancer remover and reconstructor.”
“Facial Implants - Part 1.” https://podcasts.apple.com/us/podcast/facial-implants-part-1/id1647047560. Transcript summary by WhipScribe, https://whipscribe.com/transcript-pages/facial-implants-part-1.html.